AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06506708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy + massage
Description: The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
Study NCT06340373 — intervention group
Intervention type: DEVICE
Intervention: DCB Angioplasty
Description: Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
Study NCT06557837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires and pain assessment
Description: Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
Study NCT06557837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standing sagittal whole spine X-ray
Description: Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
Study NCT06557837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic test
Description: With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
Study NCT06557837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle strength and body composition measurement
Description: Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
Study NCT02054260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgicel
Study NCT06541704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study NCT06617325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZP
Description: Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
Study NCT06617325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo at prespecified time-points.
Study NCT04869488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
Study NCT04869488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
Description: Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
Study NCT04869488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Combined With Apatinib
Description: Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
Study NCT05103514 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: There are no interventions planned for this study. This is an observational study only.
Study NCT06608108 — intervention group
Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention
Study NCT06600321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-BCAT
Description: Administered by intravenous (IV) infusion
Study NCT06009575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement Tablets
Description: The intervention group received IST and local culture-based nutrition education
Study NCT06009575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplement Tablets
Description: The intervention group received IST and local culture-based nutrition education
Study NCT06224868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
Study NCT06224868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: desufflation
Description: Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
Study NCT05743725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
Study NCT05743725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: 2 gm magnesium infusion for 30 minutes
Study NCT05935475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical landmark guided dialysis catheter insertion
Description: .: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
Study NCT05935475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECG guided dialysis catheter insertion
Description: after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
Study NCT06600321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by intravenous (IV) infusion
Study NCT06527300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHWD-870 HCl
Description: Administered P.O.
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 1
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 2
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853) Dose 3
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study NCT06503679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally
Study NCT04073706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Description: Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread.
Study NCT04073706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Description: Removal of uterus, tubes and ovaries without retroperitoneal node dissection
Study NCT04559685 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
Study NCT04559685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-Guided Focused Ultrasound device (MRgFUS)
Description: MR-Guided Focused Ultrasound device (MRgFUS) alone
Study NCT05656742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: oral vitamin D3
Study NCT05451810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study NCT06622720 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: The colorectal surgery of any type conducted in any approach in the timeframe
Study NCT06675019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.
Study NCT06675019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.
Study NCT06675019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
Study NCT06680037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azercabtagene zapreleucel (azer-cel)
Description: IV infusion
Study NCT06625775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-10203
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD
Study NCT06625775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
Study NCT06440447 — intervention group
Intervention type: OTHER
Intervention: Adult day program use
Description: Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
Study NCT06440447 — intervention group
Intervention type: OTHER
Intervention: Other community care (non-attendees)
Description: Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
Study NCT06336291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 7 μg/kg
Study NCT06336291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 10 μg/kg
Study NCT06336291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: 13 μg/kg
Study NCT06336291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 90 mg/m2
Study NCT06336291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: 110 mg/m2
Study NCT06683196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: 3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
Study NCT06683196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: 3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
Study NCT06628310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study NCT06149715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bottle Filter
Description: The household is given a Sawyer Squeeze Water Filtration System.
Study NCT06149715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bucket Filter
Description: The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
Study NCT06149715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tap Filter
Description: The household is given a Sawyer Tap Water Filtration System.
Study NCT04783376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: : Insulin, lispro and regular insulin
Description: * A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin.
Study NCT06628310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study NCT06628310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Infusion; IV Injection
Study NCT06628310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Infusion; IV Injection
Study NCT06628310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion
Study NCT04416451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Study NCT04416451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Study NCT06627322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual-combination therapy
Description: Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
Study NCT06627322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple-combination therapy
Description: Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
Study NCT06627322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G7, Pasta
Description: Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
Study NCT06627036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatoscope
Description: For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
Study NCT06627088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511 (DC-853)
Description: Administered oral dose
Study NCT06627088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY4100511 (DC-853) Administered oral dose
Description: Administered oral dose
Study NCT06627088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY4100511 (DC-853)
Description: Administered IV infusion
Study NCT06622538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation
Description: Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
Study NCT06622538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Description: Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
Study NCT06693518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
Study NCT06693518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dabigatran Etexilate 150 mg
Study NCT06693570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact Fish Skin Graft (IFSG) + Standard of Care
Description: Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06693570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06679140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuzatrelvir
Description: ibuzatrelvir tablets
Study NCT06679140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: zanubrutinib 160 mg BID orally
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanubrutinib
Description: zanubrutinib 160 mg BID orally